Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer

BACKGROUND: Therapy targeted to the human epidermal growth factor receptor type 2 (HER2) is used in combination with cytotoxic therapy in treatment of HER2+ breast cancer. Trastuzumab, a monoclonal antibody that targets HER2, has been shown pre-clinically to induce vascular changes that can increase...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Bloom, Meghan J., Jarrett, Angela M., Triplett, Todd A., Syed, Anum K., Davis, Tessa, Yankeelov, Thomas E., Sorace, Anna G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189470/
https://ncbi.nlm.nih.gov/pubmed/32345237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06868-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak